Milestone Pharmaceuticals (MIST) Cash & Current Investments (2018 - 2026)

Milestone Pharmaceuticals (MIST) has 9 years of Cash & Current Investments data on file, last reported at $184.2 million in Q1 2026.

• Quarterly Cash & Current Investments rose 1594.26% year-over-year to $184.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $184.2 million (up 1594.26% YoY) and the FY2025 annual result came in at $106.0 million, up 51.99% from the prior year.
• Cash & Current Investments rose to $184.2 million in Q1 2026, from $106.0 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $184.2 million in Q1 2026 to a low of $10.9 million in Q1 2025.
• A 5-year average of $88.5 million and a median of $79.4 million in 2024 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2025 — Cash & Current Investments tumbled 86.3% — and 2026, when it soared 1594.26%.
• Tracing MIST's Cash & Current Investments over 5 years: stood at $64.5 million in 2022, then rose by 2.21% to $66.0 million in 2023, then advanced by 5.69% to $69.7 million in 2024, then soared by 51.99% to $106.0 million in 2025, then soared by 73.86% to $184.2 million in 2026.
• The last three Cash & Current Investments figures came in at $184.2 million (Q1 2026), $106.0 million (Q4 2025), and $118.5 million (Q3 2025), per Business Quant data.